Drugs / GNC-039
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04794972 | Apr 2021 → Dec 2025 overdue | cancer, glioma | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GNC-039 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04794972 ↗ |
| Route | Intravenous | “Administration by intravenous infusion.” NCT04794972 ↗ |